Boyle Patrick M, Entcheva Emilia, Trayanova Natalia A
Department of Biomedical Engineering, Johns Hopkins University, Institute for Computational Medicine, Baltimore, MD, USA.
Expert Rev Cardiovasc Ther. 2014 Jan;12(1):17-20. doi: 10.1586/14779072.2014.864951. Epub 2013 Dec 2.
Cardiac optogenetics is an exciting new methodology in which light-sensitive ion channels are expressed in heart tissue to enable optical control of bioelectricity. This technology has the potential to open new avenues for safely and effectively treating rhythm disorders in the heart with gentle beams of light. Recently, we developed a comprehensive framework for modeling cardiac optogenetics. Simulations conducted in this platform will provide insights to guide in vitro investigation and steer the development of therapeutic applications - these are the first steps toward clinical translation. In this editorial, we review literature relevant to light-sensitive protein delivery and intracardiac illumination to provide a holistic feasibility assessment for optogenetics-based arrhythmia termination therapy. We then draw on examples from computational work to show that the optical control paradigm has undeniable advantages that cannot be attained with conventional electrotherapy. Hence, we argue that cardiac optogenetics is more than a flashy substitute for current approaches.
心脏光遗传学是一种令人兴奋的新方法,其中光敏离子通道在心脏组织中表达,以实现对生物电的光学控制。这项技术有可能开辟新途径,用柔和的光束安全有效地治疗心脏节律紊乱。最近,我们开发了一个用于心脏光遗传学建模的综合框架。在这个平台上进行的模拟将为指导体外研究和推动治疗应用的发展提供见解——这些是迈向临床转化的第一步。在这篇社论中,我们回顾了与光敏蛋白递送和心内照明相关的文献,为基于光遗传学的心律失常终止治疗提供全面的可行性评估。然后,我们借鉴计算工作中的例子,表明光学控制模式具有传统电疗法无法实现的不可否认的优势。因此,我们认为心脏光遗传学不仅仅是当前方法的花哨替代品。